Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology, Inc. (SANA)
Company Research
Source: GlobeNewswire
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Continues to Evaluate Safety, Persistence, and Function of Transplanted Cells Conference Call to be Webcast at 1:30pm PT SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announce
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAPR Newswire
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target raised by analysts at HC Wainwright from $8.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology, Inc. (NASDAQ: SANA) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating.MarketBeat
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAAccesswire
SANA
Earnings
- 11/8/24 - Miss
SANA
Sec Filings
- 1/7/25 - Form 4
- 1/3/25 - Form 4
- 12/16/24 - Form 144
- SANA's page on the SEC website